These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 26162409)

  • 1. Disease evolution and outcomes in familial AML with germline CEBPA mutations.
    Tawana K; Wang J; Renneville A; Bödör C; Hills R; Loveday C; Savic A; Van Delft FW; Treleaven J; Georgiades P; Uglow E; Asou N; Uike N; Debeljak M; Jazbec J; Ancliff P; Gale R; Thomas X; Mialou V; Döhner K; Bullinger L; Mueller B; Pabst T; Stelljes M; Schlegelberger B; Wozniak E; Iqbal S; Okosun J; Araf S; Frank AK; Lauridsen FB; Porse B; Nerlov C; Owen C; Dokal I; Gribben J; Smith M; Preudhomme C; Chelala C; Cavenagh J; Fitzgibbon J
    Blood; 2015 Sep; 126(10):1214-23. PubMed ID: 26162409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia.
    Pabst T; Eyholzer M; Haefliger S; Schardt J; Mueller BU
    J Clin Oncol; 2008 Nov; 26(31):5088-93. PubMed ID: 18768433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Familial CEBPA-mutated acute myeloid leukemia.
    Tawana K; Rio-Machin A; Preudhomme C; Fitzgibbon J
    Semin Hematol; 2017 Apr; 54(2):87-93. PubMed ID: 28637622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution.
    Hou HA; Lin YC; Kuo YY; Chou WC; Lin CC; Liu CY; Chen CY; Lin LI; Tseng MH; Huang CF; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
    Ann Hematol; 2015 Feb; 94(2):211-21. PubMed ID: 25241285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical features and management of germline CEBPA-mutated carriers.
    Pan L; Li Y; Gao H; Lai X; Cai Y; Chen Z; Li X; Wang SY
    Leuk Res; 2024 Mar; 138():107453. PubMed ID: 38442594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Investigation and clinical analysis of a family with germline CEBPA mutations in acute myeloid leukemia].
    Zhang JP; Lin D; Wang SC; Li Y; Chen YM; Wang Y; Wei H; Mi YC; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2020 Dec; 41(12):1008-1012. PubMed ID: 33445848
    [No Abstract]   [Full Text] [Related]  

  • 7. GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations.
    Green CL; Tawana K; Hills RK; Bödör C; Fitzgibbon J; Inglott S; Ancliff P; Burnett AK; Linch DC; Gale RE
    Br J Haematol; 2013 Jun; 161(5):701-705. PubMed ID: 23560626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia.
    Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Cao P; Ma X; Wang T; Zhang J; Zhang X; Lu P; Liu H
    Cancer; 2018 Aug; 124(16):3329-3338. PubMed ID: 29932212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole exome sequencing reveals a C-terminal germline variant in CEBPA-associated acute myeloid leukemia: 45-year follow up of a large family.
    Pathak A; Seipel K; Pemov A; Dewan R; Brown C; Ravichandran S; Luke BT; Malasky M; Suman S; Yeager M; ; ; Gatti RA; Caporaso NE; Mulvihill JJ; Goldin LR; Pabst T; McMaster ML; Stewart DR
    Haematologica; 2016 Jul; 101(7):846-52. PubMed ID: 26721895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group.
    Tarlock K; Lamble AJ; Wang YC; Gerbing RB; Ries RE; Loken MR; Brodersen LE; Pardo L; Leonti A; Smith JL; Hylkema TA; Woods WG; Cooper TM; Kolb EA; Gamis AS; Aplenc R; Alonzo TA; Meshinchi S
    Blood; 2021 Sep; 138(13):1137-1147. PubMed ID: 33951732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of CEBPA Mutations and Polymorphisms and their Prognostic Relevance in De Novo Acute Myeloid Leukemia Patients.
    Sarojam S; Raveendran S; Vijay S; Sreedharan J; Narayanan G; Sreedharan H
    Asian Pac J Cancer Prev; 2015; 16(9):3785-92. PubMed ID: 25987038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
    El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
    Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk.
    Park SH; Chi HS; Cho YU; Jang S; Park CJ
    Leuk Res; 2013 Nov; 37(11):1488-94. PubMed ID: 24054719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laboratory evaluation and prognostication among adults and children with CEBPA-mutant acute myeloid leukemia.
    Mendoza H; Podoltsev NA; Siddon AJ
    Int J Lab Hematol; 2021 Jul; 43 Suppl 1():86-95. PubMed ID: 34288448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA.
    Wang J; Lu R; Wu Y; Jia J; Gong L; Liu X; Lu S; Wang Y; Yan C; Liu K; Zhang X; Xu L; Jiang Q; Zhao X; Shi H; Lai Y; Huang X; Ruan G; Jiang H
    Br J Haematol; 2020 Aug; 190(4):533-544. PubMed ID: 32090321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations.
    Deng DX; Zhu HH; Liu YR; Chang YJ; Ruan GR; Jia JS; Jiang H; Jiang Q; Zhao XS; Huang XJ
    Leuk Lymphoma; 2019 Sep; 60(9):2181-2189. PubMed ID: 30773106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
    Matsuo H; Kajihara M; Tomizawa D; Watanabe T; Saito AM; Fujimoto J; Horibe K; Kodama K; Tokumasu M; Itoh H; Nakayama H; Kinoshita A; Taga T; Tawa A; Taki T; Tanaka S; Adachi S
    Blood Cancer J; 2014 Jul; 4(7):e226. PubMed ID: 25014773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Companion gene mutations and their clinical significance in AML with double mutant CEBPA.
    Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Teng W; Cao P; Nie D; Ma X; Wang T; Lu P; Liu H
    Cancer Gene Ther; 2020 Aug; 27(7-8):599-606. PubMed ID: 31477806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
    Ahn JS; Kim JY; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Minden MD; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Ann Hematol; 2016 Jan; 95(2):301-10. PubMed ID: 26537612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute myeloid leukemia due to germline CEBPA mutation in a Syrian family.
    Wafa A; Ali B; Moassass F; Kheder M; Aljapawe A; Al-Halabi B; Mrasek K; Liehr T; Al-Achkar W
    Mol Genet Genomic Med; 2022 Feb; 10(2):e1854. PubMed ID: 35032366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.